Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
9.71
-0.17 (-1.72%)
At close: Nov 7, 2025, 4:00 PM EST
9.70
-0.01 (-0.10%)
After-hours: Nov 7, 2025, 4:10 PM EST

Telix Pharmaceuticals Stock Forecast

Stock Price Forecast

The 4 analysts that cover Telix Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $21, which forecasts a 116.27% increase in the stock price over the next year. The lowest target is $20 and the highest is $22.

Price Target: $21 (+116.27%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$20$21$22$22
Change+105.97%+116.27%+126.57%+126.57%
* Price targets were last updated on Sep 23, 2025.

Analyst Ratings

The average analyst rating for Telix Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingJun '25Jul '25Aug '25Sep '25Oct '25Nov '25
Strong Buy122333
Buy111111
Hold000000
Sell000000
Strong Sell000000
Total233444

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
UBS
UBS
Strong Buy
Maintains
$23$20
Strong BuyMaintains$23$20+105.97%Sep 23, 2025
Citigroup
Citigroup
Strong Buy
Initiates
$22
Strong BuyInitiates$22+126.57%Sep 18, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$23$20
Strong BuyMaintains$23$20+105.97%Sep 10, 2025
Wedbush
Wedbush
Buy
Reiterates
$22
BuyReiterates$22+126.57%Aug 28, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Initiates
$23
Strong BuyInitiates$23+136.87%Jul 3, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock

Revenue Forecast

No data available

Revenue Growth

No data available

EPS Forecast

No data available

EPS Growth

No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.